A new study suggests that cannabinoids could help reduce the chance of a relapse for those individuals trying to quit smoking cigarettes.
It’s been shown that tobacco withdrawal is correlated with a shortfall in function involving conscious intellectual activity (aka cognitive activities), such as remembering, thinking, or reasoning.
The study in question examined the “role of CB1 cannabinoid receptors (CB1Rs) in memory impairment and spine density changes induced by nicotine withdrawal precipitated by the nicotinic antagonist mecamylamine. Drugs [designed to imitate cannabinoids] acting on the endocannabinoid system and genetically modified mice were used. ”
The researchers which conducted the study discovered that impairment of memory during “nicotine withdrawal” was hindered by the “CB1R antagonist rimonabant or the genetic deletion of CB1R in forebrain gamma-aminobutyric acidergic (GABAergic) neurons (GABA-CB1R).”
The study’s authors came to the conclusion that their findings “underline the interest of CB1R as a target to improve cognitive performance during early nicotine withdrawal. Cognitive deficits in early abstinence are associated with increased relapse risk.”
In layman’s terms, cannabinoids and the endocannabinoid system (ECS) could play an important role in reducing the chances of someone relapsing when attempting to kick the nicotine habit.